Synthesis and biological evaluation of novel bisbenzimidazoles as Escherichia coli topoisomerase IA inhibitors and potential antibacterial agents

Journal of Medicinal Chemistry

Volumn 57, Issue 12, 2014, Pages 5238-5257

  Nimesh, Hemlata ^a   Sur, Souvik ^a   Sinha, Devapriya ^a   Yadav, Pooja ^a   Anand, Prachi ^b   Bajaj, Priyanka ^a   Virdi, Jugsharan S ^a   Tandon, Vibha ^a,c  

^a UNIVERSITY OF DELHI   (India)

^b CITY UNIVERSITY OF NEW YORK   (United States)

^c JAWAHARLAL NEHRU UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 ETHYLPIPERAZIN 1 YL) 2 [2' (3,4 DIMETHOXYPHENYL) 5 BENZIMIDAZOLYL]BENZIMIDAZOLE; 5 (4 ETHYLPIPERAZIN 1 YL) 2 [2' (4 ETHOXYPHENYL) 5' BENZIMIDAZOLYL]BENZIMIDAZOLE; 5 (4 ETHYLPIPERAZIN 1 YL) 2 [2' (4 HYDROXYPHENYL) 5' BENZIMIDAZOLYL]BENZIMIDAZOLE; 5 (4 PHENYLPIPERAZIN 1 YL) 2 [2' (3,4 DIMETHOXYPHENYL) 5' BENZIMIDAZOLYL]BENZIMIDAOLE; 5 (4 PHENYLPIPERAZIN 1 YL) 2 [2' (4 HYDROXYPHENYL) 5' BENZIMIDAZOLYL]BENZIMIDAZOLE; 5 (4 PROPYLPIPERAZIN 1 YL) 2 [2' (3,4 DIMETHOXYPHENYL) 5' BENZIMIDAZOLYL]BENZIMIDAZOLE; 5 (4 PROPYLPIPERAZIN 1 YL) 2 [2' (4 ETHOXYPHENYL) 5' BENZIMIDAZOLYL]BENZIMIDAZOLE; 5 (4 PYRIDYLPIPERAZIN 1 YL) 2 [2' (3,4 DIMETHOXYPHENYL) 5' BENZIMIDAZOLYL]BENZIMIDAZOLE; 5 [4 (2 CYANOPHENYLPIPERAZIN 1 YL)] 2 [2' (3,4 DIMETHOXYPHENYL) 5' BENZIMIDAZOLYL]BENZIMIDAZOLE; 5 [4 (2 CYANOPHENYLPIPERAZIN 1 YL)] 2 [2' (4 HYDROXYPHENYL) 5' BENZIMIDAZOLYL]BENZIMIDAZOLE; 5 [4 (2 N TRIFLUOROACETYLAMINOETHYLPIPERAZIN 1 YL)] 2 [2' (4 ETHOXYPHENYL) 5' BENZIMIDAZOLYL]BENZIMIDAZOLE; 5 [4 (2 N TRIFLUOROACETYLAMINOETHYLPIPERAZIN 1 YL)] 2 [2' (4 HYDROXYPHENYL) 5' BENZIMIDAZOLYL]BENZIMIDAZOLE; 5 [4 (2 N,N DIMETHYLAMINOETHYLPIPERAZIN 1 YL) 2 [2' (3,4 DIMETHOXYPHENYL) 5' BENZIMIDAZOLYL]BENZIMIDAZOLE; 5 [4 (2 N,N DIMETHYLAMINOETHYLPIPERAZIN 1 YL)] 2 [2' (4 HYDROXYPHENYL) 5' BENZIMIDAZOLYL]BENZIMIDAZOLE; 5 [4 (2 PYRIMIDYLPIPERAZIN 1 YL) 2 [2' (4 HYDROXYPHENYL) 5' BENZIMIDAZOLYL]BENZIMIDAZOLE; 5 [4 (2 PYRIMIDYLPIPERAZIN 1 YL)] 2 [2' (3,4 DIMETHOXYPHENYL) 5' BENZIMIDAZOLYL]BENZIMIDAZOLE; 5 [4 (4 AMINOPHENYLPIPERAZIN 1 YL) 2 [2' (4 HYDROXYPHENYL) 5' BENZIMIDAZOLYL]BENZIMIDAZOLE; 5 [4 (4 AMINOPHENYLPIPERAZIN 1 YL)] 2 [2' (3,4 DIMETHOXYPHENYL) 5' BENZIMIDAZOLYL]BENZIMIDAZOLE; 5 [4 (4 FLUOROPHENYLPIPERAZIN 1 YL)] 2 [2' (3,4 DIMETHOXYPHENYL) 5' BENZIMIDAZOLYL]BENZIMIDAZOLE; 5 [4 (4 FLUOROPHENYLPIPERAZIN 1 YL)] 2 [2' (4 HYDROXYPHENYL) 5' BENZIMIDAZOYL]BENZIMIDAZOLE; 5 [4 (4 PYRIDYLPIPERAZIN 1 YL)] 2 [2' (4 ETHOXYPHENYL) 5' BENZIMIDAZOLYL]BENZIMIDAZOLE; 5 [4 [2 (N,N DIMETHYLAMINOETHYLPIPERAZIN 1 YL)]] 2 [2' (4 ETHOXYPHENYL) 5' BENZIMIDAZOLYL]BENZIMIDAZOLE; ANTIINFECTIVE AGENT; BENZIMIDAZOLE DERIVATIVE; BISBENZIMIDAZOLE DERIVATIVE; CHLORAMPHENICOL; CIPROFLOXACIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BINDING AFFINITY; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DNA BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ESCHERICHIA COLI; FEMALE; FLUORESCENCE SPECTROSCOPY; IC 50; ISOTHERMAL TITRATION CALORIMETRY; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NEUTROPENIA; NONHUMAN; SEPTICEMIA; THERMODYNAMICS;

ANIMALS; ANTI-BACTERIAL AGENTS; BENZIMIDAZOLES; DNA GYRASE; DNA TOPOISOMERASES, TYPE I; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; MOLECULAR DOCKING SIMULATION; NEUTROPENIA; PIPERAZINES; PROTEIN BINDING; SEPSIS; STRUCTURE-ACTIVITY RELATIONSHIP; THERMODYNAMICS; TOPOISOMERASE I INHIBITORS;

EID: 84903544887     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm5003028     Document Type: Article

References (64)

1. a: antibacterial agents with an improved safety profile J. Med. Chem. 2012, 55, 6916-6933
2. Black, M. T.; Hodgson, J. Novel target sites in bacteria for overcoming antibiotic resistance Adv. Drug Delivery Rev. 2005, 57, 1528-1538
3. Lima, C. D.; Wang, J. C.; Mondragon, A. Three-dimensional structure of the 67K N-terminal fragment of E. coli DNA topoisomerase I Nature 1994, 367, 138-146
4. Stewart, L.; Redinbo, M. R.; Qiu, X.; Hol, W. G.; Champoux, J. J. A model for the mechanism of human topoisomerase I Science 1998, 279, 1534-1541
5. Champoux, J. J. DNA topoisomerases: structure, function, and mechanism Annu. Rev. Biochem. 2001, 70, 369-413
6. Pommier, Y.; Leo, E.; Zhang, H.; Marchand, C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs Chem. Biol. 2010, 17, 421-433
7. Mitscher, L. A. Bacterial topoisomerase inhibitors: quinolone and pyridone antibacterial agents Chem. Rev. 2005, 105, 559-592
8. Talbot, G. H.; Bradley, J.; Edwards, J. E., Jr.; Gilbert, D.; Scheld, M.; Bartlett, J. G. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America Clin. Infect. Dis. 2006, 42, 657-668
9. Tse-Dinh, Y. C. Bacterial topoisomerase I as a target for discovery of antibacterial compounds Nucleic Acids Res. 2009, 37, 731-737
10. Nitiss, J. L. DNA topoisomerases in cancer chemotherapy: using enzymes to generate selective DNA damage Curr. Opin. Invest. Drugs 2002, 3, 1512-1516
11. Liu, L. F. DNA topoisomerase poisons as antitumor drugs Annu. Rev. Biochem. 1989, 58, 351-375
12. Drlica, K.; Malik, M.; Kerns, R. J.; Zhao, X. Quinolone-mediated bacterial death Antimicrob. Agents Chemother. 2008, 52, 385-392
13. Cheng, B.; Cao, S.; Vasquez, V.; Annamalai, T.; Tamayo-Castillo, G.; Clardy, J.; Tse-Dinh, Y. C. Identification of anziaic acid, a lichen depside from Hypotrachyna sp., as a new topoisomerase poison inhibitor PLoS One 2013, 8, e60770
14. Cheng, B.; Liu, I. F.; Tse-Dinh, Y. C. Compounds with antibacterial activity that enhance DNA cleavage by bacterial DNA topoisomerase I J. Antimicrob. Chemother. 2007, 59, 640-645
15. Black, M. T.; Stachyra, T.; Platel, D.; Girard, A. M.; Claudon, M.; Bruneau, J. M.; Miossec, C. Mechanism of action of the antibiotic NXL101, a novel nonfluoroquinolone inhibitor of bacterial type II topoisomerases Antimicrob. Agents Chemother. 2008, 52, 3339-3349
16. Black, M. T.; Coleman, K. New inhibitors of bacterial topoisomerase GyrA/ParC subunits Curr. Opin. Invest. Drugs 2009, 10, 804-810
17. Miles, T. J.; Barfoot, C.; Brooks, G.; Brown, P.; Chen, D.; Dabbs, S.; Davies, D. T.; Downie, D. L.; Eyrisch, S.; Giordano, I.; Gwynn, M. N.; Hennessy, A.; Hoover, J.; Huang, J.; Jones, G.; Markwell, R.; Rittenhouse, S.; Xiang, H.; Pearson, N. Novel cyclohexyl-amides as potent antibacterials targeting bacterial type IIA topoisomerases Bioorg. Med. Chem. Lett. 2011, 21, 7483-7488
18. Aldred, K. J.; McPherson, S. A.; Turnbough, C. L., Jr.; Kerns, R. J.; Osheroff, N. Topoisomerase IV-quinolone interactions are mediated through a water-metal ion bridge: mechanistic basis of quinolone resistance Nucleic Acids Res. 2013, 41, 4628-4639
19. Bax, B. D.; Chan, P. F.; Eggleston, D. S.; Fosberry, A.; Gentry, D. R.; Gorrec, F.; Giordano, I.; Hann, M. M.; Hennessy, A.; Hibbs, M.; Huang, J.; Jones, E.; Jones, J.; Brown, K. K.; Lewis, C. J.; May, E. W.; Saunders, M. R.; Singh, O.; Spitzfaden, C. E.; Shen, C.; Shillings, A.; Theobald, A. J.; Wohlkonig, A.; Pearson, N. D.; Gwynn, M. N. Type IIA topoisomerase inhibition by a new class of antibacterial agents Nature 2010, 466, 935-940
20. Brvar, M.; Perdih, A.; Renko, M.; Anderluh, G.; Turk, D.; Solmajer, T. Structure-based discovery of substituted 4,5′-bithiazoles as novel DNA gyrase inhibitors J. Med. Chem. 2012, 55, 6413-6426
21. Guo, C.; Pairish, M.; Linton, A.; Kephart, S.; Ornelas, M.; Nagata, A.; Burke, B.; Dong, L.; Engebretsen, J.; Fanjul, A. N. Design of oxobenzimidazoles and oxindoles as novel androgen receptor antagonists Bioorg. Med. Chem. Lett. 2012, 22, 2572-2578
22. Garcia, M. T.; Blazquez, M. A.; Ferrandiz, M. J.; Sanz, M. J.; Silva-Martin, N.; Hermoso, J. A.; de la Campa, A. G. New alkaloid antibiotics that target the DNA topoisomerase I of Streptococcus pneumoniae J. Biol. Chem. 2011, 286, 6402-6413
23. Tawar, U.; Bansal, S.; Shrimal, S.; Singh, M.; Tandon, V. Nuclear condensation and free radical scavenging: a dual mechanism of bisbenzimidazoles to modulate radiation damage to DNA Mol. Cell. Biochem. 2007, 305, 221-233
24. Singh, M.; Tandon, V. Synthesis and biological activity of novel inhibitors of topoisomerase I: 2-aryl-substituted 2-bis-1 H -benzimidazoles Eur. J. Med. Chem. 2011, 46, 659-669
25. Bansal, S.; Sinha, D.; Singh, M.; Cheng, B.; Tse-Dinh, Y. C.; Tandon, V. 3,4-Dimethoxyphenyl bis-benzimidazole, a novel DNA topoisomerase inhibitor that preferentially targets Escherichia coli topoisomerase I J. Antimicrob. Chemother. 2012, 67, 2882-2891
26. Chen, A. Y.; Yu, C.; Bodley, A.; Peng, L. F.; Liu, L. F. A new mammalian DNA topoisomerase I poison Hoechst 33342: cytotoxicity and drug resistance in human cell cultures Cancer Res. 1993, 53, 1332-1337
27. Durand, R. E.; Olive, P. L. Cytotoxicity, mutagenicity and DNA damage by Hoechst 33342 J. Histochem. Cytochem. 1982, 30, 111-116
28. Singh, M.; Sur, S.; Rastogi, G. K.; Jayaram, B.; Tandon, V. Bi- and tri-substituted phenyl rings containing bisbenzimidazoles bind differentially with DNA duplexes: a biophysical and molecular simulation study Mol. BioSyst. 2013, 9, 2541-2553
29. Ozbey, S.; Kaynak, F. B.; Kus, C.; Goker, H. 2-(2,4-Dichlorophenyl)-5- fluoro-6-morpholin-4-yl-1 H -benzimidazole monohydrate Acta Crystallogr., Sect. E: Struct Rep. Online 2002, 58, 1062-1064
30. Kelly, D. P.; Bateman, S. A.; Martin, R. F.; Reum, M. E.; Rose, M.; Whittaker, A. R. DNA binding compounds. synthesis and characterization of boron-containing bibenzimidazoles related to the DNA minor groove binder, Hoechst 33258 Aust. J. Chem. Abstr. 1994, 47, 247-262
31. Kelly, D. P.; Bateman, S. A.; Hook, R. J.; Martin, R. F.; Reum, M. E.; Rose, M.; Whittaker, A. R. D. DNA binding compounds: synthesis and characterization of 2,5′-disubstituted bibenzimidazoles related to the DNA minor groove binder Hoechst 33258. Aust. J. Chem. 1994, 47, 1751-1769
32. Kim, J. S.; Gatto, B.; Yu, C.; Liu, A.; Liu, L. F.; LaVoie, E. J. Substituted 2,5′-bi-1 H -benzimidazoles: topoisomerase I inhibition and cytotoxicity J. Med. Chem. 1996, 39, 992-998
33. van Es, T.; Staskun, B. Reductions with Raney Alloy in acid solution J. Chem. Soc. 1965, 5775-5777
34. Vega, M. C.; Garcia, S. I.; Aymami, J.; Eritja, R.; Van der Marel, G. A.; Van Boom, J. H.; Rich, A.; Coll, M. Three-dimensional crystal structure of the A-tract DNA dodecamer d(CGCAAATTTGCG) complexed with the minor-groove-binding drug Hoechst 33258 Eur. J. Biochem. 1994, 222, 721-726
35. 2 Nucleic Acids Res. 1996, 24, 4882-4889
36. Boege, F.; Straub, T.; Kehr, A.; Boesenberg, C.; Christiansen, K.; Andersen, A.; Jakob, F.; Kohrle, J. Selected novel flavones inhibit the DNA binding or the DNA religation step of eukaryotic topoisomerase I J. Biol. Chem. 1996, 271, 2262-2270
37. 2: the role of hydrogen bonding in minor groove drug-DNA recognition Nucleic Acids Res. 1997, 25, 1510-1515
38. Sissi, C.; Palumbo, M. Effect of magnesium and related divaltent metal ions in topoisomerase structure and function Nucleic Acids Res. 2009, 37 (3) 702-711
39. Domainico, P. L.; Tse Dinh, Y. C. Cleavage of dT8 and dT8 phosphorothioyl analogues by Escherechia coli DNA topoisomerase I: product and rate analysis Biochemistry 1988, 27, 6365-6371
40. 2+ dependent inhibitor of HCV NS3 serine protease Bioorg. Med. Chem. Lett. 2002, 11, 2355-2359
41. Lafitte, D.; Lamour, V.; Tsvetkov, P.; Makarov, A.; Klich, M.; Deprez, P.; Moras, D.; Briand, C.; Robert, G. DNA gyrase interaction with coumarin-based inhibitors: the role of the hydroxybenzoate isopentenyl moiety and the 5′-methyl group of the noviose Biochemistry 2002, 41, 7217-7223
42. Miller, J. R.; Herberg, J. T.; Tomilo, M.; McCroskey, M. C.; Feilmeier, B. Streptococcus pneumononiae gyrase ATPase: development and validation of an assay for inhibitor discovery and characterization J. Anal. Biochem. 2007, 365, 132-143
43. Zhu, C. X.; Tse-Dinh, Y. C. The acidic triad conserved in type IA DNA topoisomerases is required for binding of Mg(II) and subsequent conformational change J. Biol. Chem. 2000, 275, 5318-5322
44. Zhang, Z.; Cheng, B.; Tse-Dinh, Y. C. Crystal structure of a covalent intermediate in DNA cleavage and rejoining by Escherichia coli DNA topoisomerase I Proc. Natl. Acad. Sci. U. S. A. 2011, 108, 6939-6944
45. Baker, N. M.; Rajan, R.; Mondragon, A. Structural studies of type I topoisomerases Nucleic Acids Res. 2009, 37, 693-701
46. 2+ binding and DNA religation by bacterial topoisomerase I via introduction of an additional positive charge into the active site region Nucleic Acids Res. 2008, 36, 4788-4796
47. Kakkar, R.; Suruchi; Grover, R. Theoretical study of molecular recognition by Hoechst 33258 derivatives J. Biomol. Struct. Dyn. 2005, 23, 37-47
48. Chen, S. J.; Wang, J. C. Identification of active site residues in Escherichia coli DNA topoisomerase I J. Biol. Chem. 1998, 273, 6050-6056
49. Wolber, G.; Dornhofer, A. A.; Langer, T. Efficient overlay of small organic molecules using 3D pharmacophores J. Comput.-Aided Mol. Des. 2006, 20, 773-788
50. Perdih, A.; Wolber, G.; Solmajer, T. Molecular dynamics simulation and linear interaction energy study of d -Glu-based inhibitors of the MurD ligase J. Comput.-Aided Mol. Des. 2013, 27, 723-738
51. Methods for Dilution Susceptibility Test for Bacteria that Grow Aerobically, 8th ed.; Approved Standard M07-A8; Clinical Laboratory and Standards Institute: Wayne, PA, 2009.
52. Annamalai, T.; Dani, N.; Cheng, B.; Tse-Dinh, Y. C. Analysis of DNA relaxation and cleavage activities of recombinant Mycobacterium tuberculosis DNA topoisomerase I from a new expression and purification protocol BMC Biochem. 2009, 10, 18
53. Reimer, L. G.; Stratton, C. W.; Reller, L. B. Minimum inhibitory and bactericidal concentrations of 44 antimicrobial agents against three standard control strains in broth with and without human serum Antimicrob. Agents Chemother. 1981, 19, 1050-1055
54. Domanico, P. L.; Tse-Dinh, Y. C. Mechanistic studies on E. coli DNA topoisomerase I: divalent ion effects J. Inorg. Biochem. 1991, 42, 87-96
55. Castelli, S.; Vieira, S.; D'Annessa, I.; Katkar, P.; Musso, L.; Dallavalle, S.; Desideri, A. A derivative of the natural compound kakuol affects DNA relaxation of topoisomerase IB inhibiting the cleavage reaction Arch. Biochem. Biophys. 2013, 530, 7-12
56. Mancini, G.; D'Annessa, I.; Coletta, A.; Chillemi, G.; Pommier, Y.; Cushman, M.; Desideri, A. Binding of an indenoisoquinoline to the topoisomerase-DNA complex induces reduction of linker mobility and strengthening of protein-DNA interaction PLoS One 2012, 7, e51354
57. Sandeep, G.; Nagasree, K. P.; Hanisha, M.; Kumar, M. M. AUDocker LE: A GUI for virtual screening with AUTODOCK Vina BMC. Res. Notes 2011, 4, 445
58. Kaplan, W.; Littlejohn, T. G. Swiss-PDB Viewer (Deep View) Briefings Bioinf. 2001, 2, 195-197
59. Wolber, G.; Langer, T. LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters J. Chem. Inf. Model. 2005, 45, 160-169
60. Reyes, N.; Aggen, J. B.; Kostrub, C. F. In vivo efficacy of the novel aminoglycoside ACHN-490 in murine infection models Antimicrob. Agents Chemother. 2011, 55, 1728-1733
61. Xiao, X. Y.; Hunt, D. K.; Zhou, J.; Clark, R. B.; Dunwoody, N.; Fyfe, C.; Grossman, T. H.; O'Brien, W. J.; Plamondon, L.; Ronn, M.; Sun, C.; Zhang, W. Y.; Sutcliffe, J. A. Fluorocyclines. 1. 7-Fluoro-9-pyrrolidinoacetamido-6- demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent J. Med. Chem. 2012, 55, 597-605
62. Andes, D.; Craig, W.; Nielsen, L. A.; Kristensen, H. H. In vivo pharmacodynamic characterization of a novel plectasin antibiotic, NZ2114, in a murine infection model Antimicrob. Agents Chemother. 2009, 53, 3003-3009
63. Zuluaga, A. F.; Salazar, B. E.; Rodriguez, C. A.; Zapata, A. X.; Agudelo, M.; Vesga, O. Neutropenia induced in outbred mice by a simplified low-dose cyclophosphamide regimen: characterization and applicability to diverse experimental models of infectious diseases BMC Infect. Dis. 2006, 6, 55
64. Reyes, N.; Aggen, J. B.; Kostrub, C. F. In vivo efficacy of the novel aminoglycoside ACHN-490 in murine infection models Antimicrob. Agents Chemother. 2011, 55, 1728-1733